Vivos Therapeutics Price Target Slashed to $2.50 as 2025 Revenue Jumps 16%
H.C. Wainwright cut Vivos Therapeutics’ price target to $2.50 from $7.00 as shares hovered near $1.01 after its Sleep Center of Nevada acquisition. Full-year 2025 revenue rose 16% to $17.5 million, led by a $4.8 million boost in sleep testing and $2.2 million in treatments.
1. Analyst Downgrade
H.C. Wainwright cut the price target for Vivos Therapeutics to $2.50 from $7.00, reflecting concerns over near-term profitability after shares traded around $1.01.
2. Strategic Shift via Acquisition
The company is refocusing on a medical provider-focused model following its June 2025 acquisition of the Sleep Center of Nevada, aiming to expand its network of trained clinicians.
3. Strong 2025 Revenue Performance
Full-year 2025 revenue climbed 16% to $17.5 million, driven by a $4.8 million rise in sleep testing services and $2.2 million in patient treatments.
4. Market Valuation and Share Performance
Shares trade near $1.00, within a 52-week range of $0.96 to $7.95, giving the company a market capitalization of about $5.9 million.